Center for Cardiovascular Research, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA.
Tecnologico de Monterrey, Centro de Biotecnologia-FEMSA, Monterrey, NL 264610, Mexico.
Int J Mol Sci. 2019 May 19;20(10):2474. doi: 10.3390/ijms20102474.
Cardiovascular diseases are the leading cause of mortality worldwide. It is widely known that non-resolving inflammation results in atherosclerotic conditions, which are responsible for a host of downstream pathologies including thrombosis, myocardial infarction (MI), and neurovascular events. Macrophages, as part of the innate immune response, are among the most important cell types in every stage of atherosclerosis. In this review we discuss the principles governing macrophage function in the healthy and infarcted heart. More specifically, how cardiac macrophages participate in myocardial infarction as well as cardiac repair and remodeling. The intricate balance between phenotypically heterogeneous populations of macrophages in the heart have profound and highly orchestrated effects during different phases of myocardial infarction. In the early "inflammatory" stage of MI, resident cardiac macrophages are replaced by classically activated macrophages derived from the bone marrow and spleen. And while the macrophage population shifts towards an alternatively activated phenotype, the inflammatory response subsides giving way to the "reparative/proliferative" phase. Lastly, we describe the therapeutic potential of cardiac macrophages in the context of cell-mediated cardio-protection. Promising results demonstrate innovative concepts; one employing a subset of yolk sac-derived, cardiac macrophages that have complete restorative capacity in the injured myocardium of neonatal mice, and in another example, post-conditioning of cardiac macrophages with cardiosphere-derived cells significantly improved patient's post-MI diagnoses.
心血管疾病是全球范围内导致死亡的主要原因。众所周知,未解决的炎症会导致动脉粥样硬化,从而导致一系列下游病理,包括血栓形成、心肌梗死(MI)和神经血管事件。巨噬细胞作为先天免疫反应的一部分,是动脉粥样硬化各个阶段最重要的细胞类型之一。在这篇综述中,我们讨论了控制巨噬细胞在健康和梗死心脏中功能的原则。更具体地说,心脏巨噬细胞如何参与心肌梗死以及心脏修复和重塑。在心肌梗死后的不同阶段,心脏中表型异质的巨噬细胞之间的复杂平衡具有深远而高度协调的影响。在 MI 的早期“炎症”阶段,驻留的心脏巨噬细胞被来自骨髓和脾脏的经典激活的巨噬细胞取代。随着巨噬细胞群体向另一种激活表型转变,炎症反应消退,进入“修复/增殖”阶段。最后,我们描述了心脏巨噬细胞在细胞介导的心脏保护中的治疗潜力。有希望的结果表明了创新的概念;一种方法是利用卵黄囊来源的心脏巨噬细胞的一个子集,在新生小鼠受损的心肌中有完全的修复能力;另一个例子是,用心脏球源性细胞对心脏巨噬细胞进行后处理,显著改善了患者心肌梗死后的诊断。